Drugs / RG-1550
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02132403 | Aug 2014 → Apr 2015 | malignant pancreatic neoplasm | University of Illinois at Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT00096057 | May 2004 → Dec 2007 | breast cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00066547 | May 2003 → ? | breast cancer | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00770354 | Sep 2008 → Aug 2010 | breast carcinoma | Antisoma Research | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG-1550 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109362 ↗ |
| Known as | AS1402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00770354 ↗ |
| Known as | BTH1704 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02132403 ↗ |
| Known as | HuHMFG1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00096057 ↗ |
| Known as | Humanized Human Milk Fat Globule-1 | “An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and...” NCT00066547 ↗ |
| Known as | R-1550 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109362 ↗ |
| Known as | THEREX | “An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and...” NCT00066547 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody HuHMFG1” NCT00066547 ↗ |
| Route | Intravenous | “Patients receive monoclonal antibody HuHMFG1 IV over 1-3 hours” NCT00066547 ↗ |
| Target | MUC1 | “targets the aberrantly glycosylated antigen MUC1” PMID 21878535 ↗ Aug 2011 |